Two Ebola Treatments Prove Highly Effective In A Clinical Trial
SUITING UP In the Congolese city of Beni, a doctor dons protective gear prior to seeing patients with possible Ebola infections. Early reports from a clinical trial in Congo found that two drugs were better at preventing death from the disease than other treatments.
Two Ebola treatments have proven to be effective in preventing death during a clinical trial conducted amid the ongoing outbreak in Congo, preliminary data suggest.
The trial began in November, with participants randomly given one of four experimental treatments (SN: 3/16/19, p. 9). Data from 499 patients reviewed August 9 suggest that those people taking one of two antibody treatments — mAb114 or REGN-EB3 — had a greater chance of survival than those on the antiviral drug remdesivir or the antibody treatment ZMapp. Researchers reported the trial results in a news release August 12, but these findings have yet to be finalized.
Since its inception, The National Digest has been dedicated to providing authoritative and thought-provoking insights into trending topics and the latest happenings.